Search for Clinical Trial Results

Chronic Infantile Neurological Cutaneous Articular Syndrome - 7 Studies Found
Status | Study |
Terminated |
Study Name: Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease Condition:
Date: 2008-10-09 Interventions: Drug: Canakinumab |
Completed |
Study Name: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condition:
Interventions: Drug: Canakinumab (ACZ885) 6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with |
Completed |
Study Name: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease Condition:
Interventions: Drug: ACZ885 |
Completed |
Study Name: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase Condition:
Interventions: Drug: canakinumab canakinumab |
Terminated |
Study Name: HL2351 CAPS Phase II Study Condition: Cryopyrin‑Associated Periodic Syndromes (CAPS) Date: 2016-05-10 Interventions: Drug: HL2351 The dose will be adjusted based on disease activities |
Completed |
Study Name: The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada Condition: Cryopyrin Associated Periodic Syndrome Date: 2010-03-25 Interventions: Drug: canakinumab (company code: ACZ885D) |
Completed |
Study Name: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients Condition:
|